Systemic Lupus Erythematosus News and Research

RSS

Systemic lupus erythematosus (SLE) is the form of the disease that most people are referring to when they say "lupus." The word "systemic" means the disease can affect many parts of the body. The symptoms of SLE may be mild or serious. Although SLE usually first affects people between the ages of 15 and 45 years, it can occur in childhood or later in life as well.

Study reveals that Medicaid beneficiaries with lupus not following treatment plans

Medicaid beneficiaries with lupus are not adequately following their treatment plans, and this puts them at risk for poor health outcomes, according to research presented this week at the American College of Rheumatology Annual Meeting in San Diego. For most lupus medications, fewer than one in three beneficiaries were found to be adherent.

28 Oct 2013

DPP-4 inhibitors may reduce risk of autoimmune diseases

Dipeptidyl peptidase-4 inhibitors commonly used to control blood sugar levels in people with type 2 diabetes may also reduce the risk of autoimmune diseases in these patients, according to research presented this week at the American College of Rheumatology Annual Meeting in San Diego.

28 Oct 2013

Children born to mothers with lupus have twice the risk of autism spectrum disorders

According to research presented this week at the American College of Rheumatology Annual Meeting in San Diego, children born to mothers with lupus may be at twice the risk of autism spectrum disorders than those born to mothers without the disease.

28 Oct 2013

Rituximab drug may be safe, effective for immunoglobulin G4-related disease treatment

Rituximab (Rituxan) — a drug commonly used rheumatoid arthritis, granulomatosis with polyangiitis (formerly Wegener's), and certain types of cancers — may be a safe and effective treatment for immunoglobulin G4-related disease (commonly called IgG4-RD), according to research presented this week at the American College of Rheumatology Annual Meeting in San Diego.

28 Oct 2013

Lupus disparities: Young, black women have highest rate of developing lupus

Young, black women have the highest rate of developing lupus and are most likely to be diagnosed at a younger age than whites and during childbearing years, according to a new University of Michigan study of lupus in Southeastern Michigan.

25 Oct 2013

Study shows need for improved detection of sepsis for all women in labor

Rates of severe sepsis and deaths from sepsis among U.S. women hospitalized for delivery have risen sharply over the last decade, reports a study in the October issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.

24 Sep 2013

Abbvie, Ablynx Ink Up To $840M RA, SLE Collaboration

...

23 Sep 2013

Abbvie, Ablynx ink license agreement to develop anti-IL-6R Nanobody against inflammatory diseases

Ablynx and AbbVie today announced that they have entered into a global license agreement to develop and commercialize the anti-IL-6R Nanobody, ALX-0061, to treat inflammatory diseases.

23 Sep 2013

Rigel plans to focus on completing three clinical programs for ITP, DLE and dry eye disease

Rigel Pharmaceuticals, Inc. today announced its plans to focus the Company's resources on the completion of three lead clinical programs. These efforts include commencing a Phase 3 clinical study of fostamatinib, an oral SYK inhibitor, in Immune Thrombocytopenic Purpura pending discussions with regulatory agencies.

5 Sep 2013

EULAR announces recipients of Meritorious Service Award

EULAR today announced the recipients of the 13th annual Meritorious Service Award at the opening of the European League Against Rheumatism Annual Congress.

14 Jun 2013

Lupus Foundation of America announces Career Development Award and new summer fellowships

The Lupus Foundation of America, the only national force dedicated to solving the cruel mystery of lupus, announced recipients of five new summer fellowships and the Foundation's first-ever Career Development Award.

3 Jun 2013

Idera to present data from Phase 2 trial of IMO-3100 in patients with psoriasis at IID 2013

Idera Pharmaceuticals today announced presentation of data from its randomized, double-blind, placebo-controlled Phase 2 trial that showed improvements from baseline of up to 90% in Psoriasis Area Severity Index scores in patients with moderate to severe plaque psoriasis following four weeks of treatment with the Toll-like Receptor antagonist IMO-3100.

8 May 2013

Hospital for Special Surgery receives grant for new genomics center to study autoimmune diseases

Hospital for Special Surgery in New York City has received a $5.6 million grant from The Tow Foundation to establish the Hospital for Special Surgery Genomics Center.

25 Apr 2013

Nanogels to attack lupus: an interview with Dr Look and Dr Fahmy, Yale University

Nanogels are synthetic particles that can be used for drug delivery. They are approximately 100 nm to 200 nm in diameter, and are made from safe, biocompatible materials: a gel-like interior and a lipid exterior.

24 Apr 2013

Nanogel-based delivery of mycophenolic acid ameliorates systemic lupus erythematosus

Systemic lupus erythematosus (SLE) is disease in which the immune system mistakenly attacks healthy tissues, resulting in inflammation and tissue damage. Current treatments are focused on suppression of the immune system, but these therapies can leave patients vulnerable to infection.

2 Mar 2013

Resolve Therapeutics, Takeda partner to develop compounds for treatment of lupus

Takeda Pharmaceutical Company Limited and Resolve Therapeutics, LLC today jointly announced that they have entered into a partnership to develop compounds for the treatment of lupus (also known as Systemic Lupus Erythematosus, or SLE) and other autoimmune diseases.

27 Feb 2013

Scientists identify specific cellular events that appear key to lupus

A team led by scientists at The Scripps Research Institute (TSRI) has identified specific cellular events that appear key to lupus, a debilitating autoimmune disease that afflicts tens of millions of people worldwide. The findings suggest that blocking this pathway in lupus-triggering cells could be a potent weapon against the disease.

5 Feb 2013

Feinstein Institute, Merck Serono to develop antibodies for treatment of SLE

Merck Serono, a division of Merck, Darmstadt, Germany, and The Feinstein Institute for Medical Research, announced today that they will collaborate to develop antibodies for the treatment of systemic lupus erythematosus (SLE).

30 Jan 2013

Immunosuppressive drugs do not increase risk of cancer in lupus patients

People who take immunosuppressive drugs to treat lupus do not necessarily increase their cancer risk according to new research led by scientists at the Research Institute of the McGill University Health Centre (RI-MUHC).

28 Jan 2013

New hope for lupus patients

A clinical trial with 149 patients suffering from the very disabling autoimmune disease systemic lupus erythematosus, has shown the effectiveness of a synthetic peptide developed by a team of researchers led by CNRS biologist Slyviane Muller at the Institut de Biologie Moleculaire (IBMC) in Strasbourg, France.

25 Jan 2013

Systemic Lupus Erythematosus News and Research

Study reveals that Medicaid beneficiaries with lupus not following treatment plans

DPP-4 inhibitors may reduce risk of autoimmune diseases

Children born to mothers with lupus have twice the risk of autism spectrum disorders

Rituximab drug may be safe, effective for immunoglobulin G4-related disease treatment

Lupus disparities: Young, black women have highest rate of developing lupus

Study shows need for improved detection of sepsis for all women in labor

Abbvie, Ablynx Ink Up To $840M RA, SLE Collaboration

Abbvie, Ablynx ink license agreement to develop anti-IL-6R Nanobody against inflammatory diseases

Rigel plans to focus on completing three clinical programs for ITP, DLE and dry eye disease

EULAR announces recipients of Meritorious Service Award

Lupus Foundation of America announces Career Development Award and new summer fellowships

Idera to present data from Phase 2 trial of IMO-3100 in patients with psoriasis at IID 2013

Hospital for Special Surgery receives grant for new genomics center to study autoimmune diseases

Nanogels to attack lupus: an interview with Dr Look and Dr Fahmy, Yale University

Nanogel-based delivery of mycophenolic acid ameliorates systemic lupus erythematosus

Resolve Therapeutics, Takeda partner to develop compounds for treatment of lupus

Scientists identify specific cellular events that appear key to lupus

Feinstein Institute, Merck Serono to develop antibodies for treatment of SLE

Immunosuppressive drugs do not increase risk of cancer in lupus patients

New hope for lupus patients

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News